Controversies in osteoporosis management: Concerns about bisphosphonates and when are "drug holidays" required?
McClung, Michael R.. (2013) Controversies in osteoporosis management: Concerns about bisphosphonates and when are "drug holidays" required? Clinical Obstetrics and Gynecology. 56(4), pp. 743 - 748. https://doi.org/10.1097/GRF.0b013e3182a98295
|Authors||McClung, Michael R.|
Bisphosphonates are effective treatments for osteoporosis. The pharmacology and observance of atypical femoral fractures in patients on long-term therapy raise questions about the need for intermittent discontinuation of treatment, a “drug holiday.” Fracture protection benefits of bisphosphonate therapy far outweigh the risk of atypical fractures for the first 10 years of therapy. However, because the fracture probability of therapy abates slowly after stopping the treatment while the risk of atypical fracture appears to decrease quickly, a “drug holiday” of 1 to 2 years should be considered after 3 to 5 years of bisphosphonate therapy except in those patients who remain at very high fracture risk.
|Keywords||osteoporosis; bisphosphonates; atypical femoral fracture; drug holiday|
|Journal||Clinical Obstetrics and Gynecology|
|Journal citation||56 (4), pp. 743 - 748|
|Publisher||Lippincott Williams and Wilkins|
|Digital Object Identifier (DOI)||https://doi.org/10.1097/GRF.0b013e3182a98295|
|Page range||743 - 748|
|Research Group||Institute for Health and Ageing|
|Place of publication||United States of America|
2views this month
0downloads this month